scholarly journals The Expression and Therapeutic Potential of Checkpoint Kinase 2 in Laryngeal Squamous Cell Carcinoma

2020 ◽  
Vol Volume 14 ◽  
pp. 2613-2622
Author(s):  
Ying Tian ◽  
Yan Wang ◽  
Shan Xu ◽  
Chao Guan ◽  
Qingfu Zhang ◽  
...  
2007 ◽  
Vol 16 (12) ◽  
pp. 2768-2772 ◽  
Author(s):  
A. J. Yoon ◽  
J. Shen ◽  
R. M. Santella ◽  
D. J. Zegarelli ◽  
R. Chen ◽  
...  

2020 ◽  
Vol 40 (1) ◽  
Author(s):  
Suziene Caroline Silva Cardoso ◽  
Andressa Duarte ◽  
Luciana Yamamoto de Almeida ◽  
Jorge Esquiche León ◽  
Alfredo Ribeiro-Silva

2016 ◽  
Vol 40 (1-2) ◽  
pp. 126-136 ◽  
Author(s):  
ChunPing Yang ◽  
ShuFeng Gao ◽  
HaiZhen Zhang ◽  
Lian Xu ◽  
JianGuo Liu ◽  
...  

Background/Aims: This study aims to investigate the effect of CD47 on the development of laryngeal squamous cell carcinoma (LSCC) and the therapeutic potential of monoclonal antibody against CD47 and its ligand SIRPα in the treatment of LSCC. Methods: We firstly detected the expressions of CD47 mRNA and protein in LSCC and para-carcinoma tissues, introduced the most efficient CD47siRNA sequence into LSCC cells by lentiviral transfection and employed three monoclonal antibodies to evaluate their anti-LSCC effects in vitro and in vivo. Results: We observed that the mRNA and protein expressions of CD47 in LSCC tissue had significant increase in LSCC tissues compared with those in para-carcinoma tissue (p < 0.05). After the treatments of three monoclonal antibodies, i.e. anti-SIRPα, anti-CD47 BRIC126, anti-CD47 B6H12.2, in rats transfected with Hep-2 cell, it has been showed that the mRNA and protein expressions of CD47 in LSCC tissue decreased, macrophage efficiency was promoted when anti-SIRPα and/or CD47siRNA were used, the amounts, viabilities and expressions of CD47 protein of tumor cell were significantly inhibited. Additionally, combined use of CD47siRNA and anti-SIRPα seemed more efficient than solo use of CD47siRNA/anti-SIRPα. Conclusion: The results suggested a critical role of CD47 in LSCC development and the promising treatment of antiCD47/SIRPα and/or CD47siRNA in LSCC.


2015 ◽  
Vol 22 (3) ◽  
pp. 704-713 ◽  
Author(s):  
Maria Vassilakopoulou ◽  
Margaritis Avgeris ◽  
Vamsidhar Velcheti ◽  
Vassiliki Kotoula ◽  
Theodore Rampias ◽  
...  

2021 ◽  
pp. 568-572
Author(s):  
Yongquan Jiang ◽  
Wanxin Cao ◽  
Yuanbo Luo ◽  
Ji Xu ◽  
Ying Li ◽  
...  

Laryngeal squamous cell carcinoma (LSCC) is the most common malignant head and neck cancer, with a 40% recurrence rate in the first 3 years after radical treatment. Recurrence of LSCC mostly comprises lymphogenous metastasis, hematogenic metastasis, and locoregional recurrence, while LSCC seeding is rarest: there are only 4 cases reported in PubMed, and none of them is one of subcutaneous seeding. We report a case with post-surgery subcutaneous seeding of LSCC. The final biopsy demonstrated that the subcutaneous seeding of the LSCC was 2 cm away from the primary lesion, with no recurrent foci observed in the larynx and tracheostoma and little relation to the primary lesion. Thus, we drew the conclusion that LSCC surgeries should stick to the principle of the non-tumor technique to prevent subcutaneous seeding.


Sign in / Sign up

Export Citation Format

Share Document